Page 2 - Independent Data News Today

A glance at some of the days highlights from the Proactive Investors US and Canada newswires

The final interim analysis, involving 800 completed patients, will be submitted to DSMB for review and recommendations on whether to...

Abstract While it is now widely accepted that host inflammatory responses contribute to lung injury, the pathways that drive severity and distinguish coronavirus disease 2019 (COVID-19) from other viral lung diseases remain poorly characterized. We analyzed plasma samples from 471 hospitalized patients recruited through the prospective multicenter ISARIC4C study and 39 outpatients with mild disease, enabling extensive characterization of responses across a full spectrum of COVID-19 severity. Pr...

With Recent Advancements, North America Is Expected To Dominate Psychedelic Drugs Market Financialnewsmedia.com News Commentary Share this article Share this article PALM BEACH, Fla., March 9, 2021 /PRNewswire/ -- The time of "Tune In… Turn On… and Dropout" psychedelics, such as certain, mushrooms and of course, LSD were not only not legal, but no researcher could even suggest studying the compounds… they were universally declared taboo. My, but how times have changed now that the baby b...

05 February 2020 Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes the announcement that its portfolio company, Achilles Therapeutics, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/II CHIRON ...

Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials Phase I/IIa CHIRON and THETIS Trials London, UK 5 February 2021 - Achilles Therapeutics ("Achilles" or the "Company"), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (I...

Revive Therapeutics plans to apply for emergency use authorization of its drug Bucillamine as a treatment for the indication.

The Deal Would Create the Largest Enterprise in the Cannabis Industry By Revenue Shares of Canadian Licensed-Producers (LPs) Aphria (TSX:APHA) (NYSE:APHA) (FRA: 10E)  and Tilray (NASDAQ:TLRY) (FRA: 2HQ)  traded higher following the news about the two companies merging. Benzinga caught up with Aphria CEO and chairman Irwin D. Simon, who will maintain those two positions in the new company, and Tilray CEO Brendan Kennedy, who will serve in the new corporation’s board of directors a...

Published: Dec 24, 2020 By Alex Keown The European Union (EU) authorized ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) in conjunction with Janssen’s Edurant (rilpivirine tablets) for the treatment of HIV-1 infection in adults who are virologically suppressed. Vocabria is intended for adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the ...

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access Revive Therapeutics Ltd. a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19. The Company is ...